Fresenius Kabi Recalls Tocilizumab Lot in US Due to Glass Particles

Fresenius Kabi has initiated a recall of a US lot of its Tyenne (tocilizumab-aazg) biosimilar after an internal investigation identified glass particles in the vials. No adverse events have been reported in connection with this recall, which is part of a series of quality-related recalls by the company affecting other products like morphine and famotidine.